Ulixertinib
| CAS No. | 869886-67-9 | Cat. No. | BCP04232 |
| Name | Ulixertinib | ||
| Synonyms | 1956366-10-1; BVD-523; BVD 523; BVD523; VRT752271; VRT752271; VRT 752271;; | ||
| Formula | C21H22Cl2N4O2 | M. Wt | 433.33 |
| Description | Ulixertinib, also known as BVD-523 and VRT752271, is an inhibitors of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. | ||
| Pathways | MAPK Pathway | ||
| Targets | MEK/ERK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.